company background image
HOWL logo

Werewolf Therapeutics NasdaqGS:HOWL Stock Report

Last Price

US$3.25

Market Cap

US$141.2m

7D

-7.1%

1Y

-2.4%

Updated

13 Jun, 2024

Data

Company Financials +

Werewolf Therapeutics, Inc.

NasdaqGS:HOWL Stock Report

Market Cap: US$141.2m

Werewolf Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Werewolf Therapeutics
Historical stock prices
Current Share PriceUS$3.25
52 Week HighUS$8.19
52 Week LowUS$1.57
Beta0.62
1 Month Change-34.08%
3 Month Change-47.07%
1 Year Change-2.40%
3 Year Change-78.29%
5 Year Changen/a
Change since IPO-79.81%

Recent News & Updates

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Recent updates

Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Jun 04
Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding

Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space

Apr 04

Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Feb 07
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too

Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

Jan 19
Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?

There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Dec 09
There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise

Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Sep 30
Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 13
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

May 06
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Jan 27
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

Oct 24
We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate

We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Jul 08
We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Mar 24
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Dec 09
Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

Shareholder Returns

HOWLUS BiotechsUS Market
7D-7.1%0.2%1.2%
1Y-2.4%7.4%20.5%

Return vs Industry: HOWL underperformed the US Biotechs industry which returned 8.4% over the past year.

Return vs Market: HOWL underperformed the US Market which returned 21.8% over the past year.

Price Volatility

Is HOWL's price volatile compared to industry and market?
HOWL volatility
HOWL Average Weekly Movement12.5%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: HOWL's share price has been volatile over the past 3 months.

Volatility Over Time: HOWL's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201746Dan Hicklinwerewolftx.com

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma.

Werewolf Therapeutics, Inc. Fundamentals Summary

How do Werewolf Therapeutics's earnings and revenue compare to its market cap?
HOWL fundamental statistics
Market capUS$141.23m
Earnings (TTM)-US$41.58m
Revenue (TTM)US$16.22m

8.7x

P/S Ratio

-3.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HOWL income statement (TTM)
RevenueUS$16.22m
Cost of RevenueUS$39.95m
Gross Profit-US$23.72m
Other ExpensesUS$17.85m
Earnings-US$41.58m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.96
Gross Margin-146.26%
Net Profit Margin-256.33%
Debt/Equity Ratio33.5%

How did HOWL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.